Sensorion has concluded patient enrolment in the P-IIa study of SENS-401, the data of which is anticipated in H1’24
The company screened a total of 33 patients for recruiting at least 27 in the P-IIa trial aimed at assessing the presence of SENS-401 in the cochlea after 7 days of administration (oral, BID) in adult patients with moderately severe to profound hearing impairment. Patients initiate treatment 7 days prior to cochlear implantation & continue with SENS-401 for an additional 42 days
SENS-401 (oral), a small molecule, protects inner ear tissue, preventing progressive or sequelae hearing impairment. SENS-401 is also being evaluated in the P-II study for preventing Cisplatin Induced Ototoxicity
Ref: Sensorion | Image: Sensorion
Related News:- Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
